Special Issue "Marine Natural Products and Liver Health"
A special issue of Marine Drugs (ISSN 1660-3397). This special issue belongs to the section "Marine Pharmacology".
Deadline for manuscript submissions: 29 February 2024 | Viewed by 474
Special Issue Editor
Interests: chronic liver disease; marine natural products; gut microbiota; hepatic stellate cells; peroxisome-proliferator-activated receptors; liver fibrosis
Special Issue Information
Dear Colleagues,
Chronic liver disease is a global concern nowadays. Specially, nonalcoholic fatty liver disease (NAFLD) affects about one-fourth of the world’s population. NAFLD always occurs alongside metabolic dysfunction. Currently, there is no approved medicine for NAFLD. Marine natural products such as polysaccharide, polyunsaturated fatty acids and peptides have been shown to attenuate metabolic dysfunction via multiple mechanisms and thus are beneficial for liver health. Additionally, marine compounds with novel structures are promising for the treatment of chronic liver disease.
This Special Issue invites articles and reviews highlighting marine natural products’ impact on liver health. Reports of known or novel marine compounds with potential for treating chronic liver disease and studies exploring the mechanisms underlying their effects are welcome, especially those focusing the molecular targets of chronic liver disease.
Dr. Jianlin He
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- chronic liver disease
- nonalcoholic fatty liver disease
- marine compounds
- marine bioactive products
- molecular target
- liver fibrosis
- steatohepatitis
